Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder

CNS Drugs

Volumn 28, Issue 12, 2014, Pages 1191-1203

  Banaschewski, Tobias ^a   Johnson, Mats ^b   Lecendreux, Michel ^c   Zuddas, Alessandro ^d   Adeyi, Ben ^e   Hodgkins, Paul ^e,g   Squires, Liza A ^e   Coghill, David R ^f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e SHIRE   (United States)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; LISDEXAMFETAMINE; PSYCHOTROPIC AGENT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; LISDEXAMFETAMINE DIMESYLATE; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84939894836     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0193-z     Document Type: Article

References (32)

1. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-27.
2. Wigal SB, Kollins SH, Childress AC, Squires L. A 13-h laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
3. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.
4. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450-63.
5. Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395-405.
6. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364-73.
7. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1208-18.
8. Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73:977-83.
9. Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53:647-57.e1.
10. Goodman DW. Sustained treatment effect in attention-deficit/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies. Ther Clin Risk Manag. 2013;9:121-30.
11. Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1.
12. American Psychiatric Association. Neurodevelopmental disorders. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
13. Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829-40.
14. Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G. Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I63-71.
15. Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care. 2004;42:210-20.
16. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). 2000. http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011WFIRS-P.pdf. Accessed 18 Mar 2013.
17. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Weiss Functional Impairment Rating Scale (WFIRS) instructions. 2000. http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011WFIRSInstructions.pdf. Accessed 14 Oct 2013.
18. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/08/WC500095686.pdf. Accessed 22 Nov 2013.
19. Riley AW, Robertson JA, Forrest CB, Green BF, Rebok GW, Starfield B. Technical manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0). Baltimore: Johns Hopkins University; 2001.
20. Riley A, Starfield B, Forrest CB, Green BF, Robertson J, Rajmil L. Child Health and Illness Profile: a comprehensive assessment of health and functioning for children and adolescents. 2007. http://www.childhealthprofile.org/index.asp?pageid=49. Accessed 20 Nov 2013.
21. Coghill D. Pragmatic measures in paediatric psychopharmacology: are we getting it right? Eur Neuropsychopharmacol. 2011;21:571-83.
22. Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J. Practitioner review: quality of life in child mental health - conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50:544-61.
23. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83-105.
24. Schacht A, Escobar R, Wagner T, Wehmeier PM. Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. Atten Defic Hyperact Disord. 2011;3:335-49.
25. Estrada MD, Rajmil L, Serra-Sutton V, Tebe C, Alonso J, Herdman M, et al. Reliability and validity of the Spanish version of the Child Health and Illness Profile (CHIP) Child-Edition, Parent Report Form (CHIP-CE/PRF). Health Qual Life Outcomes. 2010;8:78.
26. Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2013;33:766-74.
27. Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709-18.
28. Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581-8.
29. Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. Prim Care Companion CNS Disord. 2012;14. doi: 10.4088/PCC.11r01336.
30. Cohen J. A power primer. Psychol Bull. 1992;112:155-9.
31. Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010;24:843-66.
32. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896-904.